Business Segment Over the counter Products that do not require a prescription and are mainly sold through retail pharmacies and the fast moving consumer goods sector, where brand recognition, marketing, and interactions with pharmacists play a key role in influencing consumer choices. Overview Key Brands Revenue Performance Emla Maltofer Magnesia Bisurada Mybulen Ovestin Solpadeine Xylocaine Topicals Topicalanaesthetic Ironsupplement Antacid Analgesic antiinflammatory Hormonereplacementtherapy Opioidanalgesic Topicalanaesthetic Revenue by segment (%) 22% of Group revenue 29% of Group gross profit Africa Middle East 37 Australasia 25 Europe CIS20 Americas15 Asia3 Revenue Revenue 2024R’million 2023 R’million %ChangeReported CER Africa Middle East 3 561 3 501 2 2 Australasia 2 430 2 278 7 4 Europe CIS 1 974 1 742 13 7 Americas 1 450 1 323 10 1 Asia 291 262 11 7 Total 9 706 9 106 7 3 Gross profit (%) 58,7 58,6 The OTC segment reported good organic growth across all regions. For FY2025, revenue increased by 1% (5% CER) to R9 812 million, buoyed by an expected stronger second half performance from Africa Middle East, which recorded full year growth of 5% (6% CER). Australasia, the second largest OTC region, grew by 1% (5% CER) and the portfolio now exceeds the region’s Prescription segment and is well positioned for future revenue growth. Europe CIS enjoyed a 2% CER growth supported by a key hormonal cream brand, Ovestin. Gross profit percentage of 58,3% was closely aligned with the prior period (FY2024: 58,7%).